This Dublin-based start-up works with the medical community to examine the human genome – also known as our complete set of DNA, including all of its genes – to better understand the role genetics play in the emergence of diseases and medical conditions.
Genomics Medicine Ireland (GMI) was established in 2015 by a group of life science entrepreneurs, investors and researchers.
It secured Series A funding of €36 million the following year from sovereign and international investors, including the Ireland Strategic Investment Fund, Arch Venture Partners, Polaris Partners and Google’s venture capital arm, GV.
The start-up recently undertook with the University of Cambridge to research the underlying genetic factors contributing to multiple sclerosis (MS).
Genomics Medicine Ireland is creating a scientific platform to examine the human genome, in order to better understand the role of genetics in disease and rare conditions, leading to new prevention strategies and treatments. The company was founded in Ireland in 2015 by a group of leading life sciences entrepreneurs, investors and researchers. Investors in the company include Amgen, Google Ventures, the Ireland Strategic Investment Fund, ArchVenture Partners and Polaris Partners. In 2016, it raised $40m in Series A funding, paving the way for 150 jobs in Dublin.